New study tests which vancomycin dosing method is safer for kidneys
NCT ID NCT05823116
First seen Jan 05, 2026 · Last updated Jun 21, 2026 · Updated 24 times
Summary
This study looked at how giving the antibiotic vancomycin continuously versus intermittently affects kidney function and injury markers. Thirty-seven hospitalized adults were randomly assigned to one of the two infusion methods. Researchers measured changes in kidney filtration rate and specific injury biomarkers to see if one method is gentler on the kidneys.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VANCOMYCIN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Kentucky
Lexington, Kentucky, 40506, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vancomycin
What this could lead to
If successful, this study could help doctors choose the safest way to give vancomycin to reduce kidney damage in hospitalized patients.
What could go wrong
This is a small, completed Phase 4 trial with only 37 participants, so results may not apply to all patients. The study measures biomarkers, not long-term health outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.